{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:08:25Z","timestamp":1786975705334,"version":"build-2736575974"},"reference-count":39,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.33474","type":"journal-article","created":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T12:23:16Z","timestamp":1637670196000},"page":"e2133474","source":"Crossref","is-referenced-by-count":13,"title":["Trends in Use of Granulocyte Colony-Stimulating Factor Following Introduction of Biosimilars Among Adults With Cancer and Commercial or Medicare Insurance From 2014 to 2019"],"prefix":"10.1001","volume":"4","author":[{"given":"Ching-Yu","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville"},{"name":"Center for Drug Evaluation and Safety, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coy D.","family":"Heldermon","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Vouri","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville"},{"name":"Center for Drug Evaluation and Safety, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haesuk","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville"},{"name":"Center for Drug Evaluation and Safety, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Wheeler","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Services, University of Florida Health Shands Cancer Hospital, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian Hemendra","family":"Ramnaraign","sequence":"additional","affiliation":[{"name":"University of Florida Health Cancer Center, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam Hoang","family":"Dang","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville"},{"name":"Center for Drug Evaluation and Safety, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,11,23]]},"reference":[{"issue":"8","key":"zoi210951r1","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jamaoncol.2018.1660","article-title":"Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology.","volume":"4","author":"Marquart","year":"2018","journal-title":"JAMA Oncol"},{"issue":"4","key":"zoi210951r2","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1007\/s11096-018-0706-9","article-title":"Pharmacovigilance in oncology.","volume":"40","author":"Baldo","year":"2018","journal-title":"Int J Clin Pharm"},{"issue":"12","key":"zoi210951r3","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.6004\/jnccn.2017.0175","article-title":"Myeloid growth factors, version 2.2017, NCCN clinical practice guidelines in oncology.","volume":"15","author":"Crawford","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"zoi210951r4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.6004\/jnccn.2008.0012","article-title":"Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice.","volume":"6","author":"Crawford","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"zoi210951r5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3816\/SCT.2003.n.002","article-title":"Epidemiology of febrile neutropenia.","volume":"1","author":"Lyman","year":"2003","journal-title":"Support Cancer Ther"},{"issue":"10","key":"zoi210951r6","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.","volume":"106","author":"Kuderer","year":"2006","journal-title":"Cancer"},{"issue":"23","key":"zoi210951r7","doi-asserted-by":"publisher","first-page":"5555","DOI":"10.1002\/cncr.25332","article-title":"Risk of mortality in patients with cancer who experience febrile neutropenia.","volume":"116","author":"Lyman","year":"2010","journal-title":"Cancer"},{"issue":"9","key":"zoi210951r8","first-page":"678","article-title":"Colony-stimulating factor prescribing patterns in patients receiving chemotherapy for cancer.","volume":"16","author":"Ramsey","year":"2010","journal-title":"Am J Manag Care"},{"issue":"7","key":"zoi210951r9","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1177\/1078155218799859","article-title":"Appropriateness of granulocyte colony-stimulating factor use in patients receiving chemotherapy by febrile neutropenia risk level.","volume":"25","author":"Baig","year":"2019","journal-title":"J Oncol Pharm Pract"},{"issue":"4","key":"zoi210951r10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1200\/JOP.2012.000662","article-title":"Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic.","volume":"9","author":"Waters","year":"2013","journal-title":"J Oncol Pract"},{"issue":"12","key":"zoi210951r11","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/jnci\/djr152","article-title":"Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes.","volume":"103","author":"Potosky","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"zoi210951r12","doi-asserted-by":"crossref","DOI":"10.1200\/OP.20.01045","article-title":"Impact of a G-CSF policy to reduce low-value care on guideline adherence and mortality.","author":"Orji","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"3","key":"zoi210951r13","doi-asserted-by":"crossref","first-page":"e14s","DOI":"10.1200\/JOP.2012.000540","article-title":"Guideline-based peer-to-peer consultation optimizes pegfilgrastim use with no adverse clinical consequences.","volume":"8","author":"Fishman","year":"2012","journal-title":"J Oncol Pract"},{"issue":"4","key":"zoi210951r14","doi-asserted-by":"publisher","first-page":"e337","DOI":"10.1200\/JOP.2017.020867","article-title":"Reducing overuse of colony-stimulating factors in patients with lung cancer receiving chemotherapy: evidence from a decision support-enabled program.","volume":"13","author":"Adeboyeje","year":"2017","journal-title":"J Oncol Pract"},{"key":"zoi210951r15","doi-asserted-by":"crossref","DOI":"10.1007\/s00520-021-06230-9","article-title":"Patient, nurse, and physician preferences: final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or on-body injector in cancer patients.","author":"Metz","year":"2021","journal-title":"Support Care Cancer"},{"issue":"7","key":"zoi210951r16","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1002\/pds.v29.7","article-title":"Understanding utilization patterns of biologics and biosimilars in the United States to support postmarketing studies of safety and effectiveness.","volume":"29","author":"Dutcher","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"zoi210951r17","first-page":"660","article-title":"Uptake and cost of biosimilar filgrastim among Medicare and Medicaid populations in 2015-2018.","volume":"27","author":"Qian","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"zoi210951r18","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.jval.2019.12.007","article-title":"Biosimilar uptake in Medicare Part B varied across hospital outpatient departments and physician practices: the case of filgrastim.","volume":"23","author":"Socal","year":"2020","journal-title":"Value Health"},{"issue":"11","key":"zoi210951r19","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1377\/hlthaff.2019.00253","article-title":"Biosimilar filgrastim uptake and costs among commercially insured, Medicare Advantage.","volume":"38","author":"Karaca-Mandic","year":"2019","journal-title":"Health Aff (Millwood)"},{"issue":"9","key":"zoi210951r20","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1001\/jama.2018.9014","article-title":"Uptake of the biologic filgrastim and its biosimilar product among the Medicare population.","volume":"320","author":"Kozlowski","year":"2018","journal-title":"JAMA"},{"issue":"12","key":"zoi210951r21","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/j.jval.2020.06.014","article-title":"Association between filgrastim biosimilar availability and changes in claim payments and patient out-of-pocket costs for biologic filgrastim products.","volume":"23","author":"Mouslim","year":"2020","journal-title":"Value Health"},{"issue":"9","key":"zoi210951r22","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.1007\/s00520-020-05295-2","article-title":"Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy.","volume":"28","author":"Gawade","year":"2020","journal-title":"Support Care Cancer"},{"issue":"3","key":"zoi210951r23","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","article-title":"Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review.","volume":"90","author":"Lyman","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"zoi210951r24","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1080\/1042819031000119262","article-title":"Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin\u2019s lymphoma receiving CHOP chemotherapy.","volume":"44","author":"Lyman","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"zoi210951r27","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00520-016-3421-x","article-title":"Burden of chemotherapy-induced febrile neutropenia hospitalizations in US clinical practice, by use and patterns of prophylaxis with colony-stimulating factor.","volume":"25","author":"Weycker","year":"2017","journal-title":"Support Care Cancer"},{"issue":"10","key":"zoi210951r28","first-page":"976","article-title":"Clinical outcomes of treatment with filgrastim versus a filgrastim biosimilar and febrile neutropenia-associated costs among patients with nonmyeloid cancer undergoing chemotherapy.","volume":"24","author":"Schwartzberg","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"issue":"10","key":"zoi210951r29","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1007\/s00520-017-3720-x","article-title":"Use of prophylactic growth factors and antimicrobials in elderly patients with cancer: a review of the Medicare database.","volume":"25","author":"Sosa","year":"2017","journal-title":"Support Care Cancer"},{"issue":"2","key":"zoi210951r30","doi-asserted-by":"publisher","first-page":"162","DOI":"10.6004\/jnccn.2017.7033","article-title":"Real-world impact of a decision support tool on colony-stimulating factor use and chemotherapy-induced febrile neutropenia among patients with breast cancer.","volume":"16","author":"Agiro","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"8","key":"zoi210951r31","doi-asserted-by":"publisher","first-page":"e1235","DOI":"10.1200\/OP.20.01047","article-title":"Primary prophylaxis with biosimilar filgrastim for patients at intermediate risk for febrile neutropenia: a cost-effectiveness analysis.","volume":"17","author":"Li","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"zoi210951r32","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.29_suppl.73","article-title":"Cost-effectiveness of filgrastim-sndz as primary prophylaxis (PP) versus secondary prophylaxis (SP) to prevent chemotherapy-induced febrile neutropenia (FN) in non-small cell lung cancer (NSCLC) patients at intermediate risk.","volume":"38","author":"Li","year":"2020","journal-title":"J Clin Oncol"},{"key":"zoi210951r33","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1200\/JCO.2019.37.27_suppl.107","article-title":"A cost-effectiveness analysis of primary prophylaxis (PP) versus secondary prophylaxis (SP) with biosimilar myeloid growth factors (MGFs) for preventing chemotherapy-induced febrile neutropenia (FN) in non-Hodgkin lymphoma (NHL) patients at intermediate risk.","volume":"37","author":"Lyman","year":"2019","journal-title":"J Clin Oncol"},{"key":"zoi210951r34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.6004\/jnccn.2020.7610","article-title":"Considerations for use of hematopoietic growth factors in patients with cancer related to the COVID-19 pandemic.","author":"Griffiths","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"8","key":"zoi210951r35","doi-asserted-by":"publisher","first-page":"e1139","DOI":"10.1200\/OP.20.00994","article-title":"Economic analysis on adoption of biosimilar granulocyte colony-stimulating factors in patients with nonmyeloid cancer at risk of febrile neutropenia within the oncology care model framework.","volume":"17","author":"Wang","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"1","key":"zoi210951r36","first-page":"102","article-title":"Factors affecting health care provider knowledge and acceptance of biosimilar medicines: a systematic review.","volume":"25","author":"Leonard","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"zoi210951r37","first-page":"e122","article-title":"Limited distribution networks stifle competition in the generic and biosimilar drug industries.","volume":"24","author":"Karas","year":"2018","journal-title":"Am J Manag Care"},{"issue":"21","key":"zoi210951r38","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1001\/jama.2017.5202","article-title":"Obstacles to the Adoption of Biosimilars for Chronic Diseases.","volume":"317","author":"Hakim","year":"2017","journal-title":"JAMA"},{"issue":"6","key":"zoi210951r39","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1007\/s00520-019-05080-w","article-title":"Trends in the use of primary prophylactic colony-stimulating factors and neutropenia-related hospitalization in elderly cancer patients receiving myelosuppressive chemotherapy in the USA: 1995-2015.","volume":"28","author":"Li","year":"2020","journal-title":"Support Care Cancer"},{"key":"zoi210951r25","volume-title":"International Classification of Diseases, Ninth Revision (ICD-9).","author":"World Health Organization","year":"1977"},{"key":"zoi210951r26","volume-title":"International Statistical Classification of Diseases, Tenth Revision (ICD-10)","author":"World Health Organization","year":"1992"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2786469\/wang_2021_oi_210951_1637073931.81692.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T12:23:33Z","timestamp":1637670213000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2786469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,23]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.33474","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,23]]}}}